Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Acebilustat (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMPIRE CF
- Sponsors Celtaxsys
- 02 Feb 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record.
- 22 Oct 2018 Results published in the Celtaxsys Media Release
- 02 Aug 2018 According to a Celtaxsys media release, full results from the trial will be presented this fall at the North American Cystic Fibrosis Foundation annual meeting.